anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is important to study persons vaccinated with candidate HIV-1 vaccines who have become HIV-1 infected for the following reasons. First, if transient HIV-1 infection is detected and then is effectively suppressed or cleared, it will be important to document the antigenic relationship between the breakthrough virus and the vaccine epitopes to attempt to answer questions about the specificity and breadth of the immune response and the determinants of immunity. A second reason is to gain a better understanding of vaccine-induced responses in those participants who are transiently or persistently HIV-1-infected compared to placebo recipients who become HIV-1-infected. If the vaccine does not prevent HIV-1 infection, it will be important to characterize the course of the disease as measured by longitudinal viral load measurements, CD4+ counts, and clinical symptoms. Understanding the breadth, magnitude, and specificity of the immune response in partially or fully immunized vaccinees after infection and the impact on clinical symptoms and disease progression can potentially result in valuable information for the subsequent design of vaccine efficacy trials and, ultimately, in consideration of potential effectiveness of HIV-1 vaccines.

Study visits occur at Days 0, 7, 14, 28, then at 2 months, 3 months, 6 months, and every 6 months thereafter. At these visits, patients are given a physical exam, blood is drawn, and a donation of genital fluids is requested at certain visits. Patients are asked to donate samples of either semen (men) or cervical secretions (women); viral load is measured and compared to the amount and types of virus in the blood. He/she may refuse to donate these genital fluids and still be eligible to remain in the study. Primary medical care or medications for HIV infection are not provided by this study.
Disclosed are methods for manufacturing a chitosan microflake. A chitosan microflake can be manufactured by two different ways. In the first method, chitosan is dissolved in a weak acidic solution to give a chitosan solution, which is then incubated for 1 to 30 days. The chitosan solution is then dried by a freeze-drying process, a thermal drying process, or a vacuum drying process so as to extract a solidified chitosan film. The solidified chitosan film is pulverized to yield a chitosan microflake which has a width at least ten fold greater than a thickness. In the second method, a multi-layered, air-gapped sheet of chitosan is manufactured first and pulverized so as to yield the chitosan microflake. The overall steps of the second method are similar to those of the fist method, and the only difference is a drying step. In the first method, drying is performed continuously without intermittence, but in the second method drying is conducted at substantially regular time intervals.
Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
<P>PROBLEM TO BE SOLVED: To remove the restriction of administering exogenous Interleukin (IL)-10; and to provide a method of enhancing endogenous IL-10 production in mammalian cells.  <P>SOLUTION: This invention relates to the method of enhancing endogenous interleukin-10 production in mammalian cells and tissues, which includes administering an effective amount of a tetracycline derivative. The method also includes enhancing interleukin-10 production by administering an effective amount of the tetracycline derivative to a mammal. Preferred tetracycline compounds are tetracycline compounds modified to reduce or eliminate antimicrobial activity thereof. The method can be used to treat medical conditions in mammals characterized by excessive IL-1 and TNF α production.  <P>COPYRIGHT: (C)2011,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a remote collecting device for measurement data allowing the hospital side to acquire the measurement data in a home medical care system at optional timing.  <P>SOLUTION: A superconductive magnet device is composed of a medical data measuring part 11, a measurement data transmitting part 22 and a measurement data receiving part 23. A measurement data buffer part 21 capable of holding the measurement data of a plurality of times is included between the medical data measuring part and the measurement data transmitting part, and the measurement data transmitting part transmits the measurement data held in the measurement data buffer part, by a command from the measurement data receiving part. The measurement data receiving part transmits a normal termination signal to the measurement data transmitting part at the normal termination of receiving, and transmits an abnormal termination signal to the measurement data transmitting part in the case of failing to confirm the normal termination of receiving the measurement data even after the lapse of a fixed time. The measurement data transmitting part deletes the measurement data stored in the measurement data buffer part, upon receiving the normal terminal signal, and retransmits the measurement data stored in the measurement data buffer part, upon receiving the abnormal termination signal.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Alzheimer's disease (AD) represents an urgent yet unmet challenge for modern society, calling for exploration of innovative targets and therapeutic approaches. Astrocytes, main homeostatic cells in the CNS, represent promising cell-target. Our aim was to investigate if deletion of the regulatory CaNB1 subunit of calcineurin in astrocytes could mitigate AD-related memory deficits, neuropathology, and neuroinflammation. We have generated two, acute and chronic, AD mouse models with astrocytic CaNB1 ablation (ACN-KO). In the former, we evaluated the ability of β-amyloid oligomers (AβOs) to impair memory and activate glial cells once injected in the cerebral ventricle of conditional ACN-KO mice. Next, we generated a tamoxifen-inducible astrocyte-specific CaNB1 knock-out in 3xTg-AD mice (indACNKO-AD). CaNB1 was deleted, by tamoxifen injection, in 11.7-month-old 3xTg-AD mice for 4.4 months. Spatial memory was evaluated using the Barnes maze; β-amyloid plaques burden, neurofibrillary tangle deposition, reactive gliosis, and neuroinflammation were also assessed. The acute model showed that ICV injected AβOs in 2-month-old wild type mice impaired recognition memory and fostered a pro-inflammatory microglia phenotype, whereas in ACN-KO mice, AβOs were inactive. In indACNKO-AD mice, 4.4 months after CaNB1 depletion, we found preservation of spatial memory and cognitive flexibility, abolishment of amyloidosis, and reduction of neurofibrillary tangles, gliosis, and neuroinflammation. Our results suggest that ACN is crucial for the development of cognitive impairment, AD neuropathology, and neuroinflammation. Astrocyte-specific CaNB1 deletion is beneficial for both the abolishment of AβO-mediated detrimental effects and treatment of ongoing AD-related pathology, hence representing an intriguing target for AD therapy.
The rising prevalence of global antibiotic resistance evokes the urgent need for novel antimicrobial candidates. Cationic lipopeptides have attracted much attention due to their strong antimicrobial activity, broad-spectrum and low resistance tendency. Herein, a library of fluoro-lipopeptide amphiphiles was synthesized by tagging a series of cationic oligopeptides with a fluoroalkyl tail via a disulfide spacer. Among the lipopeptide candidates, R6F bearing six arginine moieties and a fluorous tag shows the highest antibacterial activity, and it exhibits an interesting fluorine effect as compared to the non-fluorinated lipopeptides. The high antibacterial activity of R6F is attributed to its excellent bacterial membrane permeability, which further disrupts the respiratory chain redox stress and cell wall biosynthesis of the bacteria. By co-assembling with lipid nanoparticles, R6F showed high therapeutic efficacy and minimal adverse effects in the treatment of MRSA-induced sepsis and chronic wound infection. This work provides a novel strategy to design highly potent antibacterial peptide amphiphiles for the treatment of drug-resistant bacterial infections.
PROBLEM TO BE SOLVED: To provide a polymerizable composition which is excellent in mechanical strengths, especially in flexural strength, compression strength, and impact resistance, has good water resistance and color tone, and is especially suitable for dental use; a novel composite filler which hardly undergoes the change in color even when thermally treated, is suitably used for a polymerizable dental composition, and has a low degree of yellowing; and a polymerizable dental composition which is excellent in mechanical strengths, especially in flexural strength, compression strength, impact resistance, and abrasion resistance and contains the composite filler having good water resistance and color tone. SOLUTION: This polymerizable composition contains (A) 100 pts.wt. (meth) acrylate monomer having at least three ethylenically unsaturated groups, (B) 5-900 pts.wt. polyester di(meth)acrylate compound having ethylenically unsaturated groups, and (C) 0.01-5 pts.wt. polymerization initiator. The composite filler is prepared by polymerizing and curing the polymerizable composition and grinding the resultant cured composition. The polymerizable dental composition contains the composite filler.
INTRODUCTION: High cord radical orchidectomy (HRCO) is accepted as the standard surgical approach in testicular cancer, however low cord orchidectomy (LCRO) can reduce the morbidity of operation without worsening the oncological outcomes.
METHODS: We retrospectively re-examined the specimens of men to determine the level of spermatic cord invasion (SCI). Men who had proximal SCI with negative surgical margins after HRCO were assumed to have de-novo residual tumour if LCRO was performed. Others were assumed as oncologically similar. We examined the relation between pre-operative variables and SCI and proximal SCI to determine whether prediction of proximal SCI is possible.
RESULTS: 196 patients were included. 22 (11%) had SCI and ten (5%) had proximal SCI. Four patients with proximal SCI had positive surgical margins even after HRCO and didn't require additional local treatment. Six patients were assumed to have de-novo residual tumour if LCRO was performed. All six patients were metastatic and had systemic chemotherapy. High platelet count, tumour size, N stage, S stage and M stage were all significantly related with both SCI and proximal SCI (p < 0.05).
CONCLUSION: Due to low probability of SCI, we think LCRO can safely be performed to reduce morbidity in Stage 1 patients. Although there is a risk for residual tumour in Stage 2-3 patients, currently there is no data that residual tumour would impair the success of systemic chemotherapy. Therefore we can not assume that these patients would be negatively affected. Pre-operative data can be useful to predict the presence of proximal SCI and select appropriate patients for LCRO.
Subaortic stenosis is a CHD that can lead to left ventricular hypertrophy, heart failure, and aortic valve damage if left untreated. The gold standard treatment for subaortic stenosis is septal myectomy. However, there is no clear consensus on the surgical margins required for adequate muscle resection. In this retrospective study, we reviewed the records of 83 patients who underwent subaortic stenosis surgery between 2012 and 2020 to investigate the effect of early troponin levels on prognosis. We excluded patients with additional cardiac pathologies, hypertrophic obstructive cardiomyopathy, and valvular aortic stenosis.Troponin levels were recorded in the early post-operative period, and patients were monitored for complications such as ventricular arrhythmia, left ventricular systolic dysfunction, infective endocarditis, and pacemaker implantation. The troponin levels were significantly higher in the patients who had septal myectomy. The degree of myectomy affected the risk of complications in the early post-operative period and recurrence in the later period. However, when the gradient was substantially or completely removed by myectomy, patients experienced significant symptom improvement in the early post-operative period, and their late survival was equivalent to that of healthy individuals of the same age.Our findings suggest that monitoring troponin levels in patients undergoing septal myectomy may be beneficial in predicting the risk of complications. However, further studies are needed to establish the optimal surgical technique and extent of muscle resection required for subaortic stenosis treatment. Our study adds to the existing knowledge of the benefits and risks associated with septal myectomy as a treatment option for subaortic stenosis.
INTRODUCTION: The objective of this study was to investigate the changes in men's and women's measured height in response to weight gain above standards for the U.S. Navy and to quantify associated distortions in body mass index (BMI). We expected that some servicemembers would manipulate their measured height to comply with service standards.
MATERIALS AND METHODS: The study was a retrospective observational study. The data were housed in the Person-Event Data Environment, an individual-level administrative registry from the United States Department of Defense. All participants were active-duty U.S. Navy sailors aged 21-50 during the years 2010-2019. The main outcomes were height and weight as recorded during twice-yearly physical fitness assessments and BMI calculated as: height in pounds × 703/(height in inches)2. We assessed whether weight gain above standards was associated with an increase in height at the subsequent height-weight assessment.
RESULTS: Among the 489,020 sailors, individuals were nearly 1.5 times as likely to measure taller when they gained weight that put them above military height-weight standards as compared to those who continued to remain within standards. Men were more often out of standards and therefore their measured height increased during subsequent assessments more often than women. Increases in height depressed measures of BMI slightly.
CONCLUSIONS: Among U.S. sailors, taller height was correlated with surpassing height-based weight limits, where taller individuals were allowed to weigh more and still meet professional weight standards. Results underscore that current height-weight accountability standards may distort behavior, leading servicemembers to manipulate measurements rather than improve job-relevant fitness. Instead, greater reliance on fitness-based measures of health, such as fitness tests, may hold promise for upholding servicemember readiness. Our results highlight that when stakes are attached to a measure, individuals may work to raise their performance using strategies that are misaligned with the policy intent.
See illustrated Patient's Instructions for Use. SHAKE WELL BEFORE USING. Patients should be given the following information: It is recommended to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 3 days by releasing 4 test sprays into the air, away from the face. 

KEEPING THE PLASTIC ACTUATOR CLEAN IS VERY IMPORTANT TO PREVENT MEDICATION BUILD-UP AND BLOCKAGE. THE ACTUATOR SHOULD BE WASHED, SHAKEN TO REMOVE EXCESS WATER, AND AIR-DRIED THOROUGHLY AT LEAST ONCE A WEEK. THE INHALER MAY CEASE TO DELIVER MEDICATION IF NOT PROPERLY CLEANED. 

The actuator should be cleaned (with the canister removed) by running warm water through the top and bottom for 30 seconds at least once a week. Do not attempt to clean the metal canister or allow the metal canister to become wet. Never immerse the metal canister in water. The actuator must be shaken to remove excess water, then air-dried thoroughly (such as overnight). Blockage from medication build-up or improper medication delivery may result from failure to clean and thoroughly air-dry the actuator. 

If the actuator becomes blocked (little or no medication coming out of the mouthpiece), the blockage may be removed by washing the actuator as described above. 

If it is necessary to use the inhaler before it is completely dry, shake excess water off the plastic actuator, replace canister, shake well, test-spray twice away from face, and take the prescribed dose. After such use, the actuator should be rewashed and allowed to air-dry thoroughly. 

The action of XOPENEX HFA Inhalation Aerosol should last for 4 to 6 hours. XOPENEX HFA Inhalation Aerosol should not be used more frequently than recommended. Do not increase the dose or frequency of doses of XOPENEX HFA Inhalation Aerosol without consulting your physician. If you find that treatment with XOPENEX HFA Inhalation Aerosol becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using XOPENEX HFA Inhalation Aerosol, other inhaled drugs and asthma medication should be taken only as directed by your physician. 

Common adverse effects of treatment with inhaled beta-agonists include palpitations, chest pain, rapid heart rate, tremor, and nervousness. If you are pregnant or nursing, contact your physician about use of XOPENEX HFA Inhalation Aerosol. Effective and safe use of XOPENEX HFA Inhalation Aerosol includes an understanding of the way that it should be administered. 

Use XOPENEX HFA Inhalation Aerosol only with the actuator supplied with the product. Discard the canister after 200 sprays have been used from the 15 g canister or after 80 sprays have been used from the 8.4 g canister. Never immerse the canister in water to determine how full the canister is (“float test”). 

In general, the technique for administering XOPENEX HFA Inhalation Aerosol to children is similar to that for adults. Children should use XOPENEX HFA Inhalation Aerosol under adult supervision, as instructed by the patient's physician. (See Patient's Instructions for Use.)
The invention relates to a computer-aided triage method and a computer-aided triage system. The triage system at least comprises a hospital server, a user side and a medical care side. The user side can guide the user to log in and/or register to the triage system, obtain the medical purpose of the user and send the medical purpose of the user to the hospital server. The hospital server responds to the receipt of the medical purpose of the user, selects a corresponding department, and enables a medical care end configured in the corresponding department to be in contact with a user end used by the user, so that medical staff in the corresponding department can make an initial diagnosis for the user through the medical care end. And the user side uploads the positioning information of the user side to the hospital server under the condition of guiding the user to log in and/or register to the triage system. The medical staff selects one of the hospital server and the user terminal to send a department address to the medical staff according to the positioning information and the initial diagnosis result so as to generate a diagnosis route.
NEW MATERIAL:A compound expressed by formula I (n is 8-22; R and R1 are alkoxy or H). USE:Useful in assembling a light-responsive liposome system for medicine or agricultural chemical. The compound expressed by formula I is a compound containing a m-methoxybenzyl group which is a highly efficient light accepting group in the end of hydrophobic part and can be synthesized in good efficiency. PREPARATION:An acid chloride expressed by formula II is reacted with m- methoxybenzyl alcohol (derivative) expressed by formula III in a polar aprotic solvent and then the reaction product is subjected to after-treatment with water to afford a compound expressed by formula IV. Then the compound expressed by formula IV is condensed with phosphatidylglycerol expressed by formula V, e.g. by a method dissolving the compound expressed by formula IV, 4- dimethylaminopyridine and dicyclohexylcarbodiimide which is a condensing agent in chloroform, adding CdCl2 salt of compound expressed by formula V thereto and stirring the mixture.
The present invention provides a traditional Chinese medicine extractive and a preparation method and application of the traditional Chinese medicine extractive. The traditional Chinese medicine extractive is prepared by that peony and licorice are used as raw materials. The extractive at least contain 50 wt. % of peony total glycosides, glycyrrhizic acid and total flavonoids glycoside. The preparation method comprises: the peony and/or the licorice are dewatered, decocted and filtered; extraction liquid is merged, effective ingredients are enriched by macroporous resin, alcohol is used for elution, alcohol eluent is collected, the alcohol is recovered in the mode of decompression, and is concentrated into extractum, and the extractum is dried. The traditional Chinese medicine extractive of the present invention can be used for preparing medicines for treating chronic hepatitis B, and has the advantages of specific effective ingredients, high content, relative fixation of the content and the proportion of main ingredients, stable and controllable quality, safety, effectiveness and low cost.
Participants first receive 8 mL of Epidiolex (800 mg of cannabidiol) + 16 mL of inactive cherry syrup delivered every 12 hours for 48 hours total (4 doses) during which prescribed methadone is withheld. After 1 week, they receive 20 mL of inactive cherry syrup delivered every 12 hours for 48hours total (4 doses) during which prescribed methadone is withheld.
Fruit snacks made from sweetened dried fruits is a source of polyphenols, fiber, and other nutrients. The addition of sugar could aid in the taste, texture, and shelf life of these types of products. Fruit snacks with different levels of sugar were developed to meet various consumer needs. The postprandial glucose response in a healthy population is of interest in this regard.

Mulberry leaf extract has been shown the benefit of blood glucose regulation in multiple studies. This is mainly due to the function of the most predominant iminosugar, 1-deoxynojirimycin (DNJ), in the mulberry leaf extract which acts as α-glucosidase inhibitor. Fruit snacks containing mulberry leaf extract were developed and the postprandial metabolic response against a reference (white bread matched for carbohydrate) will be observed.
PURPOSE: A composition containing Potentilla chinensis extract for tightening pore or suppressing sebum secretion is provided to suppress SNARE(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex formulation. CONSTITUTION: A composition for tightening pore or suppressing sebum contains Potentilla chinensis extract as an active ingredient. The composition suppresses membrane fusion between synaptic vesicle and presynaptic membrane. The Potentilla chinensis extract isolated using water, ethanol, or anhydrous methanol. A pharmaceutical composition or a cosmetic composition contains the composition. The cosmetic composition is manufactured in the form of astringent, lotion, massage cream, essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, or body essence.